Dave Knapp Jun 14, 2024 3 min read Updated: Jun 14, 2024 In a troubling trend, Pharmacy Benefit Managers (PBMs) are implementing their own stringent requirements for covering GLP-1 medications, such as Saxenda, Wegovy, and Zepbound, used for the treatment of obesity
Subanalyses of EXSCEL, SUSTAIN-6 and PIONEER-6 trials suggested that patients with HF may not necessarily benefit from GLP-1RA therapy
Brand-name tirzepatide, sold as Mounjaro and Zepbound, costs between $1,000 and $1,300 per month without insurance
Modelling EuroQoL health-related utility values for diabetic complications from CODE-2 data
The second perspective will attempt to understand the analytical and organisational advantages that generative models bring to spatial planning and governance activities
Some reports show that statins reduce levels of coenzyme Q10 (CoQ10) in the body